A framework for genomic biomarker actionability and its use in clinical decision making
暂无分享,去创建一个
Vivek Subbiah | Razelle Kurzrock | Jordi Rodon | R. Kurzrock | F. Janku | R. Schwab | V. Subbiah | S. Vidwans | Filip Janku | I. Garrido-Laguna | Ignacio Garrido-Laguna | Javier Munoz | Richard Schwab | Smruti J. Vidwans | Michelle L. Turski | J. Muñoz | J. Rodón
[1] A. Tsao,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .
[2] Laurence Doyle,et al. Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures , 2011, PloS one.
[3] R. Figlin,et al. Akt inhibitors in clinical development for the treatment of cancer , 2010, Expert opinion on investigational drugs.
[4] A. Tsao,et al. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[6] A. Lièvre,et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Goozner. Drug approvals 2011: focus on companion diagnostics. , 2012, Journal of the National Cancer Institute.
[8] A. Iafrate,et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.
[9] Clarence C Lee,et al. Genomic and transcriptomic plasticity in treatment-naïve ovarian cancer , 2014, Genome research.
[10] Yongping Song,et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics , 2013, Journal of Hematology & Oncology.
[11] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[12] Il-Jin Kim,et al. FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression , 2008, Science.
[13] B. Monia,et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells , 2002, Oncogene.
[14] D. Maloney. Anti-CD20 antibody therapy for B-cell lymphomas. , 2012, The New England journal of medicine.
[15] D. Lebwohl,et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases , 2013, Annals of the New York Academy of Sciences.
[16] A. Gedman,et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T- cell acute lymphoblastic leukemia: A report from the Children's Oncology Group , 2009, Leukemia.
[17] Y. Dobashi,et al. Mammalian target of rapamycin: a central node of complex signaling cascades. , 2011, International journal of clinical and experimental pathology.
[18] Karly P Garnock-jones,et al. Dabrafenib: First Global Approval , 2013, Drugs.
[19] P. Jänne,et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. , 2006, Cancer cell.
[20] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Stefan Glück,et al. Molecular Profiling for Breast Cancer: A Comprehensive Review , 2013, Biomarkers in cancer.
[22] G. Giaccone,et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] L. Emens,et al. HER2-directed therapy for metastatic breast cancer. , 2013, Oncology.
[24] M. Yin,et al. Targeting the mTOR pathway in tumor malignancy. , 2013, Current cancer drug targets.
[25] D. V. Von Hoff,et al. Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer , 2013, Clinical Cancer Research.
[26] R. Kurzrock,et al. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Achinstein,et al. Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. , 2009, Nutrition reviews.
[28] E. Van Cutsem,et al. Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer , 2013, Clinical Cancer Research.
[29] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[30] F. Cappuzzo,et al. Clinical experience with gefitinib: an update. , 2006, Critical reviews in oncology/hematology.
[31] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[32] A. Newland,et al. Brentuximab Vedotin: A CD30‐Directed Antibody‐Cytotoxic Drug Conjugate , 2013, Pharmacotherapy.
[33] A. Ribas,et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines , 2012, Molecular Cancer.
[34] Gordon Mills,et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC , 1998, Current Biology.
[35] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[36] Alona Muzikansky,et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. , 2007, The oncologist.
[37] Razelle Kurzrock,et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Shinji Yamazaki,et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.
[39] M. Neuss,et al. Implementing a breast cancer registry and treatment plan/summary program in clinical practice: A pilot program , 2013, Cancer.
[40] Robert E. Brown,et al. Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist , 2012, Molecular Cancer Therapeutics.
[41] M. Somerfield,et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Richard J. Lee,et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. , 2013, Thyroid : official journal of the American Thyroid Association.
[43] P. L. McCormack,et al. Trametinib: First Global Approval , 2013, Drugs.
[44] P. Cluzel,et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. , 2013, Blood.
[45] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[46] S. Barth,et al. CD30 as a Therapeutic Target for Lymphoma , 2013, BioDrugs.
[47] J. Lee,et al. P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy , 2013, Oncotarget.
[48] Razelle Kurzrock,et al. Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses , 2014, Clinical Cancer Research.
[49] Jun Liang,et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. , 2012, Journal of medicinal chemistry.
[50] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[51] L. Chin,et al. Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.
[52] P. Keegan,et al. U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. , 2011, The oncologist.
[53] Jessie H. Conta,et al. Practices and Policies of Clinical Exome Sequencing Providers: Analysis and Implications , 2013, American Journal of Medical Genetics. Part A.
[54] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[55] Bohdan Waszkowycz,et al. Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer , 2013, Proceedings of the National Academy of Sciences.
[56] Vivek Subbiah,et al. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities , 2013, Orphanet Journal of Rare Diseases.
[57] J. Schellens,et al. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. , 2010, Current clinical pharmacology.
[58] N. Gray,et al. TSC1 involvement in bladder cancer: diverse effects and therapeutic implications , 2013, The Journal of pathology.
[59] A. Ciechanover,et al. Functional Interaction between SEL-10, an F-box Protein, and the Nuclear Form of Activated Notch1 Receptor* , 2001, The Journal of Biological Chemistry.
[60] P. Majumder,et al. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.
[61] M. Czuczman,et al. Use of rituximab, the new FDA-approved antibody. , 1998, Current opinion in oncology.
[62] Robin Shattock,et al. In Vitro and In Vivo: The Story of Nonoxynol 9 , 2005, Journal of acquired immune deficiency syndromes.
[63] Razelle Kurzrock,et al. PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors , 2011, Molecular Cancer Therapeutics.
[64] F. Cappuzzo,et al. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. , 2006, The New England journal of medicine.
[65] R. Kurzrock,et al. BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes , 2011, PloS one.
[66] Shinji Yamazaki,et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.
[67] R. Pazdur,et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[68] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[69] C. Sawyers,et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.